Immuncheckpoint-Inhibition – Basiswissen für die klinische Praxis

Die Immuncheckpoint-Inhibition ist eine vielversprechende Behandlungsstrategie in der Onkologie. Immuncheckpoint-Inhibitoren, zumeist monoklonale Antikörper, blockieren die inhibitorischen Signale des Immunsystems und verstärken so die Immunantwort gegen den Tumor. Dieser Übersichtsartikel vermittelt grundlegendes Wissen über die Immuncheckpoint-Inhibition und zeigt den aktuellen Stellenwert dieser Therapien in der modernen Krebstherapie.

Publication History

Article published online:
03 September 2024

• Literatur

• 1 Doroshow DB, Bhalla S, Beasley MB. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021; 18: 345-362
• 2 Chowell D, Yoo S-K, Valero C. et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat Biotechnol 2022; 40: 499-506
• 3 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 2019; 19: 133-150
• 4 Bai R, Lv Z, Xu D. et al. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res 2020; 8: 34
• 5 Samstein RM, Lee C-H, Shoushtari AN. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019; 51: 202-206
• 6 Rizvi H, Sanchez-Vega F, La K. et al. Molecular determinants of response to anti-programmed cell death (pd)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted nextgeneration sequencing. JCO 2018; 36: 633-641
• 7 Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541: 321-330
• 8 Schenkel JM, Pauken KE. Localization, tissue biology and T cell state — implications for cancer immunotherapy. Nat Rev Immunol 2023;
• 9 Derosa L, Routy B, Thomas AM. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 2022; 28: 315-324
• 10 Derosa L, Hellmann MD, Spaziano M. et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and nonsmall-cell lung cancer. Annals of Oncology 2018; 29: 1437-1444
• 11 Routy B, Lenehan JG, Miller WH. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med 2023;
• 12 Dougan M, Luoma AM, Dougan SK. et al. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021; 184: 1575-1588
• 13 Stamatouli AM, Quandt Z, Perdigoto AL. et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 2018; 67: 1471-1480
• 14 Sullivan RJ, Weber JS. Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. Nat Rev Drug Discov 2022; 21: 495-508
• 15 Johnson DB, Nebhan CA, Moslehi JJ. et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022;
• 16 Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15: 486-499
• 17 Aggarwal V, Workman CJ, Vignali DAA. LAG-3 as the third checkpoint inhibitor. Nat Immunol 2023;
• 18 Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020; 20: 651-668
• 19 Winship AL, Alesi LR, Sant S. et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat Cancer 2022; 3: 1-13
• 20 Jiang P, Sinha S, Aldape K. et al. Big data in basic and translational cancer research. Nat Rev Cancer 2022; 22: 625-639
• 21 Weilandt J, Lebahn H, Ludwig-Peitsch W. Chemotherapy following progression after immune checkpoint inhibition in metastasizing malignant melanoma: Case report and Literature Review. Aktuelle Dermatologie 2022; 48: 458-464